MRK Stock: Price, Earnings History and SEC Filings
Merck & Co., Inc. (MRK) last traded at $149.52, up 2.18% on the latest session and up 2.9% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $2.49 against an analyst estimate of $2.12, a beat of 17.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
MRK earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $2.49 | $2.12 | +17.45% |
| Jun 2026 | Aug 4, 2026 | $-0.13 | $-0.26 | +50.00% |
| Mar 2026 | Apr 30, 2026 | $-1.28 | $-1.51 | +15.23% |
| Dec 2025 | Feb 3, 2026 | $2.04 | $2.03 | +0.49% |
MRK beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How MRK reacts to earnings
Across its last 8 earnings releases, MRK moved 2.5% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | Before open | +3.83% |
| 2026-08-04 | Before open | +0.18% |
| 2026-04-30 | Before open | -1.60% |
| 2026-02-03 | Before open | +2.18% |
| 2025-10-30 | Before open | -0.35% |
| 2025-07-29 | Before open | -1.70% |
| 2025-04-24 | Before open | +1.40% |
| 2025-02-04 | Before open | -9.07% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
MRK financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $65.0B | $18.3B | $12.4B | 28.1% | $7.28 |
| 2024 | $64.2B | $17.1B | $18.1B | 26.7% | $6.74 |
| 2023 | $60.1B | $365M | $9.1B | 0.6% | $0.14 |
| 2022 | $59.3B | $14.5B | $14.7B | 24.5% | $5.71 |
| 2021 | $48.7B | $13.0B | – | 26.8% | $5.14 |
| 2020 | $41.5B | $7.1B | – | 17.0% | $2.78 |
| 2019 | $39.1B | $9.8B | – | 25.2% | $3.81 |
| 2018 | $42.3B | $6.2B | – | 14.7% | $2.32 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for MRK
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 8-K · Oct 13, 2026Officer or director change
- 10-Q · Aug 7, 2026
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 8-K · May 28, 2026Shareholder vote
- 8-K · May 22, 2026Other events, Financial statements and exhibits
- 424B5 · May 20, 2026
- 424B5 · May 18, 2026
- 10-Q · May 4, 2026
- 8-K · Apr 30, 2026Results of operations, Financial statements and exhibits
Insider filing activity
MRK insiders filed 10 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
MRK news
- Merck stock rises as its cancer strategy gets personalNov 1, 2026 · thestreet.com
- MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwindsOct 31, 2026 · finance.yahoo.com
- How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine DataOct 31, 2026 · finance.yahoo.com
- Merck (MRK) Stock Rallies As Q3 Earnings Ease Profit SqueezeOct 31, 2026 · finance.yahoo.com
- Why Merck Stock Flew Higher on FridayOct 31, 2026 · fool.com
- Eli Lilly’s Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss DrugsOct 30, 2026 · 247wallst.com
- CMMB Celebrates New Distribution Center at the Brethren Service Center with Ribbon-Cutting CeremonyOct 30, 2026 · finance.yahoo.com
- This week in charts: ESMO’s winners and losersOct 30, 2026 · biopharmadive.com
About Merck & Co., Inc.
Merck & Co., Inc. (MRK) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in NJ. Its fiscal year ends in December.